BR112013028163A2 - composition useful for the treatment of disorders of lipid metabolism - Google Patents

composition useful for the treatment of disorders of lipid metabolism

Info

Publication number
BR112013028163A2
BR112013028163A2 BR112013028163A BR112013028163A BR112013028163A2 BR 112013028163 A2 BR112013028163 A2 BR 112013028163A2 BR 112013028163 A BR112013028163 A BR 112013028163A BR 112013028163 A BR112013028163 A BR 112013028163A BR 112013028163 A2 BR112013028163 A2 BR 112013028163A2
Authority
BR
Brazil
Prior art keywords
treatment
lipid metabolism
disorders
composition useful
policosanol
Prior art date
Application number
BR112013028163A
Other languages
Portuguese (pt)
Inventor
Aleardo Koverech
Ashraf Virmani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority claimed from PCT/EP2012/057428 external-priority patent/WO2012150146A1/en
Publication of BR112013028163A2 publication Critical patent/BR112013028163A2/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição últil para o tratamento de distúrbios do metabolismo lipídico a presente invenção refere-se a uma composição últil para o tratamento de distúrbios do matabolismo lipídico, compreendendo um ou mais dos seguintes ingredientes ativos: (a) extrato de arroz fermentado com monascus purpureus, (b) pelo menos um ácido graxo ômega-3, (c) l-carnitina ou um sal desta e um ou mais dos seguintes ingredientes ativos: (d) pelo menos um policosanol ou um natural contendo policosanol; (e) resveratrol ou um extrato natural contendo resveratrol; (f) coenzima q10; e (g) pelo menos uma vitamina.Useful composition for the treatment of lipid metabolism disorders The present invention relates to a useful composition for the treatment of lipid metabolism disorders, comprising one or more of the following active ingredients: (a) Fermented rice extract with monascus purpureus, ( (b) at least one omega-3 fatty acid, (c) l-carnitine or a salt thereof and one or more of the following active ingredients: (d) at least one policosanol or natural containing policosanol; (e) resveratrol or a natural extract containing resveratrol; (f) coenzyme q10; and (g) at least one vitamin.

BR112013028163A 2011-05-03 2012-04-24 composition useful for the treatment of disorders of lipid metabolism BR112013028163A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11645263 2011-05-03
PCT/EP2012/057428 WO2012150146A1 (en) 2011-05-03 2012-04-24 Composition useful for the treatment of lipid metabolism disorders

Publications (1)

Publication Number Publication Date
BR112013028163A2 true BR112013028163A2 (en) 2017-01-10

Family

ID=57714792

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028163A BR112013028163A2 (en) 2011-05-03 2012-04-24 composition useful for the treatment of disorders of lipid metabolism

Country Status (1)

Country Link
BR (1) BR112013028163A2 (en)

Similar Documents

Publication Publication Date Title
RS54100B1 (en) Composition useful for the treatment of lipid metabolism disorders
BR112015002309A2 (en) multi-component formulation to enhance neurological function
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
NZ778131A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2014004993A3 (en) Methods of reducing ldl-p
ECSP12012097A (en) DERIVATIVES OF FUMARATE OF FATTY ACID AND ITS USES
NZ743714A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
BR112012032816A2 (en) controlled release pharmaceutical composition, and methods for reducing the dietary effect of a controlled release composition, reducing the amount of time required to achieve a stable state for metformin, to improve the bioavailability of a controlled release dosage form. matrix
BR112014029245A2 (en) methods for decreasing subtilisin / quexin type 9 protein convertase (pcsk9)
BR112014027204A2 (en) statin fatty acid conjugates and fxr agonists; compositions and method of uses
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
EA201070419A1 (en) COMPOSITION FOR REGULATING METABOLISM OF LIPIDS
BR112015002372A2 (en) compositions and methods for reducing blood alcohol content
ES2666322T3 (en) Pharmaceutical compositions for the treatment of muscular disorders
BR112014027820A2 (en) dietary control of celiac disease and food allergies
BR112015029897A2 (en) solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d and process for obtaining said composition
BR112017008033A2 (en) For oral administration the pharmaceutical composition comprising the taxane
BR112015013322A2 (en) solid cosmetic composition, method for its production, product and cosmetic method
BR112014000182A2 (en) bitterness masking
BR112014027738A2 (en) Talole fatty acid that is modified by saponification for use, food supplement, and food compound
BR112014000773A8 (en) NICOTINAMIDE COMPOSITIONS AND THERAPEUTIC USE THEREOF
WO2014082027A3 (en) Antioxidant dietary supplement
AR092187A1 (en) FORTIFYING COMPOSITION FOR PREMATURE BABY
BR112015008031A2 (en) solid cosmetic composition, process for its production, product and cosmetic method
BR112013018057A2 (en) A composition comprising opc and omega-3 for preventing and / or inhibiting the development of diabetic retinopathy.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements